Insights & Analysis
There’s one constant in healthcare: change. Count on us to break down the trends so you can stay up to date. Follow our take on each piece of this deep, intertwined, and often perplexing industry to find opportunities and practical approaches to move healthcare forward.
Featured Content
Premium Content
Premium Content
Christie Teigland Contributes to NQF’s Disparities Report
Avalere’s Teigland was selected by the National Quality Forum to participate in the Disparities Standing Committee.
Avalere’s Take on the MA/PD Landscape Files Release
The Centers for Medicare & Medicaid Services (CMS) just released the annual Landscape Files containing data on plan participation, beneficiary premiums, and benefit designs for the 2018 Part D — Medicare's prescription drug benefit — and Medicare Advantage (MA) markets.
Dan Mendelson Op-ed Featured in Medtech Insight
Avalere's President and Founder, Dan Mendelson, recently wrote a column about the new strategies that device manufacturers should take in this era of healthcare.
FDARA Builds on Progress in Expanded Access
The FDA Reauthorization Act of 2017 (FDARA), which was signed into law on August 18, 2017, calls on FDA to examine underlying barriers to access to investigational drugs.
Pharmacist Immunization Authority Associated with Higher Seasonal Influenza Immunization Rates
Avalere recently partnered with the National Association of Chain Drug Stores (NACDS) to explore the role that pharmacists can play in the uptake of seasonal influenza immunizations.
Our Take on the Senate Passage of the FDA User Fee Reauthorization Bill
Today, the Senate voted to pass H.R.2430, the FDA Reauthorization Act of 2017.
Part D Premiums Update: What You Need to Know
On July 31, the Centers for Medicare & Medicaid Services (CMS) announced that the base Part D premium will be $35 for 2018.
Takeaways from the Updated Better Care Reconciliation Act (BCRA)
As the Senate prepares to begin debate on a revised version of the Better Care Reconciliation Act (BCRA) next week, Avalere offers the following observations on select components of the legislation:
Elizabeth Carpenter to Present at NGA Summer Meeting
Elizabeth Carpenter, Senior Vice President, will present on July 15 at the National Governors Association Summer Meeting in Providence, RI, in a governors-only session entitled “The Future of Health Care.”
Update on The Medicare Trustee’s Report: IPAB Is Not Triggered
Today, the Medicare Trustees delivered to Congress their annual report on the financial operations and status of the program.
Medicaid Funding Reform: Impact on Dual-Eligible Beneficiaries
The Better Care Reconciliation Act (BCRA) would cap Medicaid funding to states. In this analysis, Avalere worked with The SCAN Foundation to examine how BCRA Medicaid changes would impact dual-eligible beneficiaries. We compare these outcomes to the impact of the House-approved American Health Care Act.
Avalere’s Take on the Quality Payment Program Proposed Rule
Today, the Centers for Medicare & Medicaid Services (CMS) released the proposed rule that makes changes to the Quality Payment Program (QPP) for 2018, the second year of the program created by the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA).
21st Century Cures: What to Expect This Summer
The 21st Century Cures Act presents medical product manufacturers, patient groups, and advocacy organizations with a unique opportunity to plan for upcoming policy changes that are aimed at accelerating the pace of development and approval of new therapies.
Avalere to Participate in National Academies of Medicine Panel
On Tuesday, June 13, Christie Teigland, PhD, will participate in a panel discussion entitled “Measuring and Reporting Social Risk Factors” as part of a dissemination meeting on the report series “Accounting for Social Risk Factors in Medicare Payment,” sponsored by the National Academies of Medicine.
Avalere Deepens Focus on FDA Regulatory Matters with Three New Hires
Tom Kraus, who most recently served as the chief of staff at the FDA, will be joining Avalere as senior vice president.
Five Obstacles to Competition in the United States Biologics Market
Biosimilars have the opportunity to foster competition, but policy and market barriers limit the growth of a functioning market.
Avalere and FasterCures Co-Author Blog Post Featured in Health Affairs
Blog post features key learnings from the Patient-Perspective Value Framework.
Our Take on The President’s Budget for Fiscal Year 2018
Today, the Trump Administration released its budget for fiscal year 2018 (FY 2018). The budget provides the President's recommendations for how the Congress should fund the government and marks the beginning of the FY 2018 budget season.
VA Formulary Coverage Much More Limited than Ohio Medicaid
Across 8 therapeutic areas, the Veteran's Administration (VA) National Formulary covers 49 percent fewer drugs than Ohio's largest Medicaid managed care plan and 68 percent fewer drugs than the Ohio Medicaid preferred drug list (PDL).
Payer Insights on the Use of Patient Data
Avalere recently partnered with the National Pharmaceutical Council to examine payers' perspectives regarding the use of patient data and how it can be used to shape care delivery, improve system efficiencies, and achieve better health outcomes.